Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes contribute to increased dyspnoea that is the key symptom of an exacerbation. Inhaled long acting bronchodilators not only control symptoms b...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bangabandhu Sheikh Mujib Medical University
2022-02-01
|
| Series: | Bangabandhu Sheikh Mujib Medical University Journal |
| Subjects: | |
| Online Access: | https://www.banglajol.info/index.php/BSMMUJ/article/view/56597 |
| _version_ | 1817984393281536000 |
|---|---|
| author | Shamim Ahmed Mohammed Atiqur Rahman Shah Ashiqur Rahman Ashiq Choudhury |
| author_facet | Shamim Ahmed Mohammed Atiqur Rahman Shah Ashiqur Rahman Ashiq Choudhury |
| author_sort | Shamim Ahmed |
| collection | DOAJ |
| description |
COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes contribute to increased dyspnoea that is the key symptom of an exacerbation. Inhaled long acting bronchodilators not only control symptoms but also prevent exacerbations of chronic obstructive pulmonary disease (COPD). The purpose of the study was to compare the efficacy between Indacaterol-Glycopyrronium and salmeterol fluticasone (SFC) in preventing COPD exacerbations during 24 weeks of treatment. This randomised active-controlled trial was conducted at Department of Respiratory Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka involving 200 patients with COPD exacerbations. Patients were randomly divided into two groups; & treated with Indacaterol- Glycopyrronium 110/50 ug o.d. & Salmeterol-Fluticasone (50/500 ug b.i.d.) (SFC) respectively; & follow-up was done after 12 and 24 weeks. The FEV1 was significantly higher at 12 and 24 weeks in the Indacateol- Glycopyrronium group compared with SFC. Statistically significant improvements in peak FVC was observed in Indacaterol- Glycopyrronium when compared to SFC at week 12 and week 24. Our study result showed that Indacaterol-Glycopyrronium was superior to Salmeterol-Fluticasone in terms of prevention and optimal management of COPD exacerbation.
BSMMU J 2021; 14(3): 43-49
|
| first_indexed | 2024-04-13T23:44:06Z |
| format | Article |
| id | doaj.art-0db5069496094836999400d3ff4d380b |
| institution | Directory Open Access Journal |
| issn | 2074-2908 2224-7750 |
| language | English |
| last_indexed | 2024-04-13T23:44:06Z |
| publishDate | 2022-02-01 |
| publisher | Bangabandhu Sheikh Mujib Medical University |
| record_format | Article |
| series | Bangabandhu Sheikh Mujib Medical University Journal |
| spelling | doaj.art-0db5069496094836999400d3ff4d380b2022-12-22T02:24:23ZengBangabandhu Sheikh Mujib Medical UniversityBangabandhu Sheikh Mujib Medical University Journal2074-29082224-77502022-02-0114310.3329/bsmmuj.v14i3.56597Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-FluticasoneShamim Ahmed0Mohammed Atiqur Rahman1Shah Ashiqur Rahman2Ashiq Choudhury3Department of Respiratory Medicine, BSMMU, Dhaka, BangladeshDepartment of Respiratory Medicine, BSMMU, Dhaka, BangladeshDepartment of Respiratory Medicine, BSMMU, Dhaka, BangladeshDepartment of Respiratory Medicine, BSMMU, Dhaka, Bangladesh COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes contribute to increased dyspnoea that is the key symptom of an exacerbation. Inhaled long acting bronchodilators not only control symptoms but also prevent exacerbations of chronic obstructive pulmonary disease (COPD). The purpose of the study was to compare the efficacy between Indacaterol-Glycopyrronium and salmeterol fluticasone (SFC) in preventing COPD exacerbations during 24 weeks of treatment. This randomised active-controlled trial was conducted at Department of Respiratory Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka involving 200 patients with COPD exacerbations. Patients were randomly divided into two groups; & treated with Indacaterol- Glycopyrronium 110/50 ug o.d. & Salmeterol-Fluticasone (50/500 ug b.i.d.) (SFC) respectively; & follow-up was done after 12 and 24 weeks. The FEV1 was significantly higher at 12 and 24 weeks in the Indacateol- Glycopyrronium group compared with SFC. Statistically significant improvements in peak FVC was observed in Indacaterol- Glycopyrronium when compared to SFC at week 12 and week 24. Our study result showed that Indacaterol-Glycopyrronium was superior to Salmeterol-Fluticasone in terms of prevention and optimal management of COPD exacerbation. BSMMU J 2021; 14(3): 43-49 https://www.banglajol.info/index.php/BSMMUJ/article/view/56597Indacaterol Glycopyrronium, SFC (salmeterol flu"casone), COPD exacerba"on |
| spellingShingle | Shamim Ahmed Mohammed Atiqur Rahman Shah Ashiqur Rahman Ashiq Choudhury Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone Bangabandhu Sheikh Mujib Medical University Journal Indacaterol Glycopyrronium, SFC (salmeterol flu"casone), COPD exacerba"on |
| title | Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone |
| title_full | Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone |
| title_fullStr | Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone |
| title_full_unstemmed | Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone |
| title_short | Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone |
| title_sort | effectiveness of indacaterol glycopyrronium in preventing copd exacerbations in comparison to salmeterol fluticasone |
| topic | Indacaterol Glycopyrronium, SFC (salmeterol flu"casone), COPD exacerba"on |
| url | https://www.banglajol.info/index.php/BSMMUJ/article/view/56597 |
| work_keys_str_mv | AT shamimahmed effectivenessofindacaterolglycopyrroniuminpreventingcopdexacerbationsincomparisontosalmeterolfluticasone AT mohammedatiqurrahman effectivenessofindacaterolglycopyrroniuminpreventingcopdexacerbationsincomparisontosalmeterolfluticasone AT shahashiqurrahman effectivenessofindacaterolglycopyrroniuminpreventingcopdexacerbationsincomparisontosalmeterolfluticasone AT ashiqchoudhury effectivenessofindacaterolglycopyrroniuminpreventingcopdexacerbationsincomparisontosalmeterolfluticasone |